ABOS Acumen Pharmaceuticals, Inc. Total Debt to Capital

Serving as the primary valuation tool, this Acumen Pharmaceuticals (ABOS) price chart demonstrates a debt load of 0.72. Acumen Pharmaceuticals specializes in developing methods to combat dementia by blocking harmful proteins in brain cells. High authority among physicians confirms the brand's potential, while the primary development vector is focused on conducting tests of the selective drug ACU193 to qualitatively alter the course of Alzheimer's disease.

This ratio measures the proportion of debt obligations within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on external financing. By analyzing the leverage ratio—total debt to equity—investors determine the margin of safety for Acumen Pharmaceuticals (ABOS) to modernize logistics and ensure the operation of contract manufacturing plants preparing drugs for clinical trials.